WEIL CONSULTING Ltd provides advice and support to accelerate the translation of Process Development to Phase I/II clinical trials. Experience in the rapid translation and scale-up of ATMP manufacture, biochemical engineering, IMPD authorship and CTA submission, commercial scale manufacture of genetically modified cell/gene therapy, and bioprocess design enables a diverse skill set to be shared with clients.
Dr Ben Weil, Director of WEIL CONSULTING Ltd & Head of GMP Process Engineering at Royal Free London NHS Foundation Trust, has established and manages the GMP Process Engineering group at the Centre for Cell, Gene and Tissue Therapeutics (CCGTT) who drive development of cost-effective Advanced Therapy Medicinal Product (ATMP) provision through scale up/out, automation, and closed system bioprocessing to minimise delivery costs and maximise accessibility of new therapeutics for patients.
Feel free to drop us a line below!
* Required fields